Oxford
-
Canaan-Backed Biotech Gives Orphan Receptor a Home and New Role in Gut Cancer Drugs
ThirtyFiveBio aims to treat gastrointestinal cancer by targeting a so-called orphan receptor called GPR35. The biotech startup is revealing its science at the American Association of Cancer Research annual meeting.
-
Adaptimmune, TCR2 Therapeutics to Combine in Marriage of Cell Therapy Developers
Adaptimmune and TCR2 Therapeutics have complementary technologies and an aligned strategy of developing cell therapies for solid tumors, but this marriage is preceded by divorce. Before consummating the TCR2 deal, Adaptimmune ended an alliance with a larger pharmaceutical company.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Artificial Intelligence, BioPharma
RNA therapies startup Ochre Bio lands $30M to take on chronic liver disease
Ochre Bio’s Series A financing will support development of RNA therapies for chronic liver disease. Longer term, the company aims to develop therapies that regenerate organs in patients, potentially avoiding the need for organ transplants.
-
Pharma, Artificial Intelligence, BioPharma
Sanofi bets big on AI again, paying $100M to start drug R&D pact with Exscientia
Sanofi’s new alliance with artificial intelligence biotech Exscientia spans up to 15 small molecule drugs in cancer and immunology. If drugs from the partnership reach the market, Exscientia could earn as much as $5.2 billion in milestone payments.
-
Artificial Intelligence, BioPharma
AI powered and now publicly traded, Exscientia adds $464M to fuel drug R&D
Exscientia’s IPO and private placement raised $464 million to support its artificial intelligence-based approach to discovering and developing new drugs. In addition to partnerships with pharmaceutical companies, an alliance with the Bill & Melinda Gates Foundation is focused on developing antiviral drugs for future pandemics.
-
Biotech IPO wave rolls on as Werewolf, Vaccitech raise $230M for clinical trials
Vaccitech and Werewolf Therapeutics joined the public markets, raising a combined $230 million. The vaccine developer and the cancer immunotherapy biotech will apply the IPO proceeds toward clinical development of their respective pipelines.
-
Evox has big pharma partners. Now it has $95M to bring its own drugs to the clinic
In the past year, Evox Therapeutics has inked alliances with two big pharma companies. The Series C financing now positions the biotech to advance to the clinic with its own exosome-based therapies.
-
Startups see new promise in old insight about viruses to stop cancer
Researchers have known for decades that viruses can beat back cancer. But it’s been hard to design a virus that does the trick. A new wave of startups is optimistic they have found the keys.
-
Common steroid appears to lower death rate among severely ill Covid-19 patients
Data from a large Phase II/III study in the U.K. showed that patients requiring respiratory support who received the drug dexamethasone died at lower rates than those who received standard treatments alone.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Hospitals, Artificial Intelligence
Mayo Clinic selects U.K startup’s AI tool to gain insights on Covid’s effect on the heart
A young UK startup is collaborating on a research study with Mayo Clinic to use an FDA-cleared automated echocardiogram assessment and quantification tool to unlock the mysteries of how Covid-19 attacks the heart.
-
Artificial Intelligence, BioPharma
AI drug development partnership between GlaxoSmithKline, Exscientia yields first drug candidate
The in vivo molecule was discovered under a two-year-old partnership between the two companies to discovery drugs using artificial intelligence. It will be developed for COPD.
-
Artificial Intelligence, BioPharma
Microsoft, Oxford Biomedica to apply cloud, machine learning to improving gene therapy
The partnership between the US software giant and UK-based biotech company is designed to increase the yield and improve the purity of lentiviral vectors in gene therapy.
-
Genomics raises $32.5M to develop genetic database technology for drug development
Boston-based drugmaker Vertex Pharmaceuticals leads the round and also enters partnership with UK firm to aid its own drug development efforts.
-
BioPharma, Pharma, Startups, SYN
PsiOxus doubles-down with BMS in $936M deal
PsiOxus Therapeutics has signed a second agreement with Bristol-Myers Squibb (BMS), this time for worldwide rights to its ‘armed’ oncolytic virus NG-348, currently in the preclinical research phase.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
